XLResearcher profile · from public sources
Xiuning Le
Targets
Filled chips are declared by the researcher; the others come from publications (number of works).
Now
Trials, publications and grants since Nov 2024.
Publication
BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor against Uncommon EGFR Mutations.
Molecular cancer therapeutics, Nov 2026
Publication
Osimertinib plus Gefitinib in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer and EGFR (C797X) Mutation Following First-Line Osimertinib: ORCHARD.
Clinical cancer research : an official journal of the American Association for Cancer Research, Oct 2026
Publication
P-Loop/αC-Helix Compressing Mutations and Exon 20 Insertions in EGFR-Mutant NSCLC: A Rapidly Evolving Therapeutic Landscape.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Sept 2026
Publication
Genomic Profiling of Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer after Progression on First-line Osimertinib: Phase II ORCHARD Study.
Clinical cancer research : an official journal of the American Association for Cancer Research, Sept 2026
Publication
Rare Fusions, Real Targets: Ultraprecision Oncology in Lung Cancer.
Cancer discovery, Aug 2026
Publication
Real-World Patient Characteristics, Mutational Landscape, and Outcomes in Advanced/Metastatic HER2-Mutant Non-Small Cell Lung Cancer.
JCO precision oncology, Jun 2026
Publication
Real-World Experience of Tarlatamab in Extensive-Stage Small Cell Lung Carcinoma Showed Promising Systemic and Intracranial Efficacy With Higher Neurologic Toxicity.
JCO precision oncology, Apr 2026
Publication
Loss of Payload Sensitivity and Other Mechanisms of Resistance to T-DXd in HER2-Mutant NSCLC: Implications for Subsequent Responsiveness to HER2 TKIs.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, Jan 2026
Publication
Therapeutic responses in patients with advanced NSCLC enrolled in early-phase clinical trials at MD Anderson.
NPJ precision oncology, Jan 2026
Publication
Precision oncology in resected EGFR-mutant NSCLC.
The Lancet. Oncology, Jan 2026
Publication
Development of PET/CT-clinical nomograms for predicting lymph node metastasis in primary lung cancer.
European radiology, Dec 2025
Publication
Precise diagnosis of small invasive pulmonary nodules driven by single-cell immune signatures in peripheral blood.
Nature communications, Dec 2025
Publication
MET Overexpression Is Associated with Superior Immunotherapy Benefit in Advanced Non-Small Cell Lung Cancer.
Cancers, Nov 2025
Publication
Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC - mechanisms and evolving treatment approaches.
Nature reviews. Clinical oncology, Nov 2025
Publication
Radiomics for Dynamic Lung Cancer Risk Prediction in USPSTF-Ineligible Patients.
Cancers, Oct 2025
Publication
Poziotinib for EGFR exon 20-insertion NSCLC: Clinical efficacy of the phase 2 ZENITH trial and differential impact of EGFR exon 20 insertion location on sensitivity.
Nature communications, Sept 2025
Co-authors
Who links you
Enter another researcher's profile link or ID to see who has published with both of you.
You have published with Jia Wu directly.
Is this you? Request a correction or removal: support@frontlightresearch.com
Report an error